S92 Efficacy Of Once-daily Tiotropium Respimat(R) 5  g From Five Phase Iii Trials In Adults With Symptomatic Asthma

Abstract

Background Recent clinical trials have indicated that the long-acting antimuscarinic agent tiotropium, a once-daily long-acting bronchodilator, may provide benefit to patients with symptomatic asthma. We investigated primary efficacy data (lung function, risk of severe exacerbation and seven-question Asthma Control Questionnaire [ACQ-7] response) from five Phase III, randomised, double-blind, parallel-group trials that evaluated the efficacy and safety of once-daily tiotropium add-on versus placebo add-on (all tiotropium doses delivered via the Respimat SoftMist inhaler) in adults with symptomatic asthma on inhaled corticosteroid (ICS) + long-acting beta2-agonist (LABA) maintenance therapy. Methods Two 48-week trials of tiotropium Respimat 5 mug (PrimoTinA-asthma: NCT00776984, NCT00772538) in patients on high-dose ICS (>800 mug budesonide or equivalent) + LABA; two 24-week trials of tiotropium Respimat 5 mug and 2.5 mug (MezzoTinA-asthma: NCT01172808, NCT01172821) in patients on moderate-dose ICS (400-800 mug budesonide or equivalent); one 12-week trial of tiotropium Respimat 5 mug and 2.5 mug (GraziaTinA-asthma: NCT01316380) in patients on low-dose ICS (200-400 mug budesonide or equivalent). Results 3476 patients were treated, of whom 1128 received tiotropium Respimat 5 mug. Once-daily tiotropium Respimat 5 mug significantly improved lung function (Table) in patients with not fully controlled asthma receiving low- to high-dose ICS. In addition, tiotropium Respimat 5 mug reduced the risk of severe exacerbations versus placebo (co-primary end point) in patients on high-dose ICS + LABA (hazard ratio 0.79; p = 0.0343), and there was an increase in ACQ-7 responder rate (co-primary end point) with the5 mug dose (odds ratio 1.32; p = 0.0308) compared with placebo in patients on moderate-dose ICS. Conclusion Once-daily tiotropium Respimat significantly improves lung function in adult patients with symptomatic asthma receiving a range of doses of ICS, including even high-dose ICS + LABA, suggesting a potential role for this treatment as add-on to ICS in adults with symptomatic asthma. (Table Presented).